Contineum Therapeutics, Inc. (CTNM) Form 8-K — Nov 3, 2026
Contineum Therapeutics reported third-quarter 2026 results with a net loss of $18.7 million, wider than $12.8 million a year earlier, driven by R&D spending of $16.0 million (up 45%) for the PIPE-791 IPF program. The company held $244.5 million in cash and securities as of September 30, 2026, with runway through mid-2029 — one year past estimated completion of its Phase 2 PROPEL-IPF trial.
Key figures
- Revenue
- 0
- Cash Position
- 244500000
- Cash runway
- through mid-2029
- Trial sites
- over 100 sites in 16 countries
- Net loss q3 2025
- $12.8 million
- Ga expense q3 2026
- $5.0 million
- Rd expense q3 2026
- $16.0 million
- Ga expense yoy change
- 26 percent increase
- Rd expense yoy change
- 45 percent increase
- Trial patients target
- 324
- Net loss nine months 2026
- $48.3 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.